Last reviewed · How we verify
Pyridostigmine, Tacrolimus
At a glance
| Generic name | Pyridostigmine, Tacrolimus |
|---|---|
| Also known as | Pyridostigmine Bromide, Prograf/FK506 |
| Sponsor | Da, Yuwei, M.D. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
- Clinical Prognosis and Progression of Myasthenia Gravis Patients
- Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pyridostigmine, Tacrolimus CI brief — competitive landscape report
- Pyridostigmine, Tacrolimus updates RSS · CI watch RSS
- Da, Yuwei, M.D. portfolio CI